Cardiogenic shock is defined in the MONDO ontology as a rare cardiac condition with severely decreased cardiac output, hypoperfusion and end-organ dysfunction despite adequate intravascular volume. Presentation ranges from subtle hemodynamic alterations to overt cardiovascular collapse. The Orphanet-derived prevalence field gives approximately 1 to 5 per 10,000. Onset category and inheritance are not supplied in this packet.

The definition lists dyspnea, crackles, elevated jugular venous pressure, altered mental state, abnormal pulse pressure, oliguria, cold extremities and increased serum lactate. HPO annotations include, as very frequent (80-99%), abnormal EKG, hypotension, abnormal left ventricular function and low-output congestive heart failure. Frequent (30-79%) annotations include congestive heart failure, myocardial infarction, cardiac arrest, dyspnea, reduced consciousness, arrhythmia, oliguria, hypoxemia, cyanosis and edema. Occasional (5-29%) annotations include confusion, mitral regurgitation, metabolic acidosis and hepatomegaly. Affected systems are listed as cardiovascular and respiratory.

No genes, inheritance patterns or molecular mechanism are supplied in this packet, so the genetic basis is not characterized here.

No diagnostic methods are supplied in this packet. The definition names hypoperfusion, end-organ dysfunction and increased serum lactate among commonly reported features.

No FDA approved-treatment or foundational-therapy records are supplied in this packet, so treatment information is unknown here. Orphan-drug records list Hemoximer and tilarginine acetate as designated for treatment of cardiogenic shock, and alfimeprase as designated for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. Designation does not constitute FDA approval.

Prognosis is not certified in this packet; no natural history information is supplied.

ClinicalTrials.gov lists numerous registered studies. Examples in the packet include NCT07583446, a phase 2 istaroxime study in acute heart failure-cardiogenic shock (Seismic Pharmaceuticals; recruiting; 2026-09-09 to 2028-12-01); NCT04682483, the Cardiogenic Shock Working Group Registry (Tufts Medical Center; recruiting; 2017-12-04 to 2027-12-01); and NCT07562932, comparing norepinephrine and dopamine initiation (Chonnam National University Hospital; recruiting; 2026-06-16 to 2032-05-31). Individuals interested in clinical trials can search ClinicalTrials.gov.